Alto Neuroscience (ANRO) Enterprise Value (2024 - 2026)

Alto Neuroscience has reported Enterprise Value for 4 years, with the latest figure at -$263.8 million in Q1 2026.

• Quarterly Enterprise Value fell 64.08% year-over-year to -$263.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$263.8 million (down 64.08% YoY) and the FY2025 annual result came in at -$176.5 million, down 4.93% from the prior year.
• Enterprise Value declined to -$263.8 million in Q1 2026 per ANRO's latest filing, from -$176.5 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$82.5 million in Q4 2023 and troughed at -$263.8 million in Q1 2026.
• A 4-year average of -$171.8 million and a median of -$172.3 million in 2024 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value slumped 103.76% in 2024, then increased 24.15% in 2025.
• Over 4 years, Enterprise Value stood at -$82.5 million in 2023, then tumbled by 103.76% to -$168.2 million in 2024, then fell by 4.93% to -$176.5 million in 2025, then plunged by 49.45% to -$263.8 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$263.8 million, -$176.5 million, and -$137.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.